CircuLex Human PCSK9 ELISA Kit

MBL Life Sciences

Catalog No: MBL-CY-8079

The CircuLex Research Product Human PCSK9 ELISA Kit is used for the quantitative measurement of Human PCSK9 in serum, plasma, cell culture medium and other biological media. It can be used for 96 Assays.

Product Specifications

• Application: ELISA
• Measurement Range: 0.16 - 10 ng/mL
• Sensitivity: better than 0.154 ng/ml of sample.

Citations for CircuLex Human PCSK9 ELISA Kit – 47 Found

Noguchi, Tohru; Katsuda, Shoji; Kawashiri, Masa-Aki; Tada, Hayato; Nohara, Atsushi; Inazu, Akihiro; Yamagishi, Masakazu; Kobayashi, Junji; Mabuchi, Hiroshi. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis. 2010;210(1):166-72. 

Cariou, Bertrand; Le Bras, Maëlle; Langhi, Cédric; Le May, Cédric; Guyomarc'h-Delasalle, Béatrice; Krempf, Michel; Costet, Philippe. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis. 2010;211(2):700-2. 

Costet, P; Hoffmann, M M; Cariou, B; Guyomarc'h Delasalle, B; Konrad, T; Winkler, K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010;212(1):246-51. 

Noguchi, Tohru; Kobayashi, Junji; Yagi, Kunimasa; Nohara, Atsushi; Yamaaki, Naoto; Sugihara, Masako; Ito, Naoko; Oka, Rie; Kawashiri, Masa-Aki; Tada, Hayato; Takata, Mutsuko; Inazu, Akihiro; Yamagishi, Masakazu; Mabuchi, Hiroshi. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. Atherosclerosis. 2011;217(1):165-70. 

Mayne, Janice; Dewpura, Thilina; Raymond, Angela; Bernier, Lise; Cousins, Marion; Ooi, Teik Chye; Davignon, Jean; Seidah, Nabil G; Mbikay, Majambu; Chrétien, Michel. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clinical Chemistry. 2011;57(10):1415-23. 

Vergès, Bruno; Duvillard, Laurence; Brindisi, Marie Claude; Gautier, Emmanuel; Krempf, Michel; Costet, Philippe; Cariou, Bertrand. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis. 2011;219(1):342-8. 

Cariou, Bertrand; Le May, Cédric; Costet, Philippe. Clinical aspects of PCSK9. Atherosclerosis. 2011;216(2):258-65. 

Persson, Lena; Henriksson, Peter; Westerlund, Eli; Hovatta, Outi; Angelin, Bo; Rudling, Mats. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arteriosclerosis, Thrombosis, And Vascular Biology. 2012;32(3):810-4. 

Kawashiri, Masa-Aki; Nohara, Atsushi; Noguchi, Tohru; Tada, Hayato; Nakanishi, Chiaki; Mori, Mika; Konno, Tetsuo; Hayashi, Kenshi; Fujino, Noboru; Inazu, Akihiro; Kobayashi, Junji; Mabuchi, Hiroshi; Yamagishi, Masakazu. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. The American Journal Of Cardiology. 2012;109(3):364-9. 

Lindholm, Marie W; Elmén, Joacim; Fisker, Niels; Hansen, Henrik F; Persson, Robert; Møller, Marianne R; Rosenbohm, Christoph; Ørum, Henrik; Straarup, Ellen M; Koch, Troels. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Molecular Therapy : The Journal Of The American Society Of Gene Therapy. 2012;20(2):376-81. 

Cameron, Jamie; Bogsrud, Martin P; Tveten, Kristian; Strøm, Thea Bismo; Holven, Kirsten; Berge, Knut Erik; Leren, Trond P. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. Translational Research : The Journal Of Laboratory And Clinical Medicine. 2012;160(2):125-30. 

Huijgen, R; Fouchier, S W; Denoun, M; Hutten, B A; Vissers, M N; Lambert, G; Kastelein, J J P. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. Journal Of Lipid Research. 2012;53(5):979-983. 

Cariou, Bertrand; Langhi, Cédric; Le Bras, Maëlle; Bortolotti, Murielle; Lê, Kim-Anne; Theytaz, Fanny; Le May, Cédric; Guyomarc'h-Delasalle, Béatrice; Zaïr, Yassine; Kreis, Roland; Boesch, Chris; Krempf, Michel; Tappy, Luc; Costet, Philippe. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutrition & Metabolism. 2013;10(1):4. 

Lee, Chan Joo; Lee, Yong-Ho; Park, Sahng Wook; Kim, Kwang Joon; Park, Sungha; Youn, Jong-Chan; Lee, Sang-Hak; Kang, Seok-Min; Jang, Yangsoo. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism: Clinical And Experimental. 2013;62(6):845-50. 

Le Bras, Maëlle; Roquilly, Antoine; Deckert, Valérie; Langhi, Cédric; Feuillet, Fanny; Sébille, Véronique; Mahé, Pierre-Joachim; Bach, Kalyane; Masson, Damien; Lagrost, Laurent; Costet, Philippe; Asehnoune, Karim; Cariou, Bertrand. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. The Journal Of Clinical Endocrinology And Metabolism. 2013;98(4):E732-6. 

Mayne, Janice; Ooi, Teik Chye; Raymond, Angela; Cousins, Marion; Bernier, Lise; Dewpura, Thilina; Sirois, Francine; Mbikay, Majambu; Davignon, Jean; Chrétien, Michel. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids In Health And Disease. 2013;12:70. 

Peticca, Patricia; Raymond, Angela; Gruslin, Andrée; Cousins, Marion; Adetola, Ejibunmi; Abujrad, Hussein; Mayne, Janice; Ooi, Teik Chye. Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood. Isrn Endocrinology. 2013:341632. 

Tremblay, André J; Lamarche, Benoît; Guay, Valérie; Charest, Amélie; Lemelin, Valéry; Couture, Patrick. Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men. The American Journal Of Clinical Nutrition. 2013;98(1):32-41. 

Conway, V; Couture, P; Richard, C; Gauthier, S F; Pouliot, Y; Lamarche, B. Impact of buttermilk consumption on plasma lipids and surrogate markers of cholesterol homeostasis in men and women. Nutrition, Metabolism, And Cardiovascular Diseases : Nmcd. 2013;23(12):1255-62. 

Lambert, Gilles; Petrides, Francine; Chatelais, Mathias; Blom, Dirk J; Choque, Benjamin; Tabet, Fatiha; Wong, Gida; Rye, Kerry-Anne; Hooper, Amanda J; Burnett, John R; Barter, Philip J; Marais, A David. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. Journal Of The American College Of Cardiology. 2014;63(22):2365-73. 

Werner, Christian; Hoffmann, Michael M; Winkler, Karl; Böhm, Michael; Laufs, Ulrich. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascular Pharmacology. 2014;62(2):94-102. 

Abujrad, H; Mayne, J; Ruzicka, M; Cousins, M; Raymond, A; Cheesman, J; Taljaard, M; Sorisky, A; Burns, K; Ooi, T C. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis. 2014;233(1):123-9. 

Jia, Yan-jun; Zhang, Yan; Liu, Jun; Guo, Yuan-lin; Xu, Rui-xia; Li, Jian-jun. Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chinese Journal Of Integrative Medicine. 2016;22(2):96-100. 

Bonde, Ylva; Breuer, Olof; Lütjohann, Dieter; Sjöberg, Stefan; Angelin, Bo; Rudling, Mats. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. Journal Of Lipid Research. 2014;55(11):2408-15. 

Mbikay, Majambu; Sirois, Francine; Simoes, Sonia; Mayne, Janice; Chrétien, Michel. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. Febs Open Bio. 4:755-62. 

Iggman, David; Rosqvist, Fredrik; Larsson, Anders; Arnlöv, Johan; Beckman, Lena; Rudling, Mats; Risérus, Ulf. Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). Journal Of The American Heart Association. 2014;3(5):e001095. 

Xu, Rui-Xia; Li, Sha; Zhang, Yan; Li, Xiao-Lin; Guo, Yuan-Lin; Zhu, Cheng-Gang; Li, Jian-Jun. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids In Health And Disease. 2014;13:188. 

Ghosh, Moumita; Gälman, Cecilia; Rudling, Mats; Angelin, Bo. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. Journal Of Lipid Research. 2015;56(2):463-9. 

Xu, Rui-Xia; Liu, Jun; Li, Xiao-Lin; Li, Sha; Zhang, Yan; Jia, Yan-Jun; Sun, Jing; Li, Jian-Jun. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. Journal Of Translational Medicine. 2015;13:87. 

Starr, Amanda E; Lemieux, Valérie; Noad, Jenny; Moore, Jasmine I; Dewpura, Thilina; Raymond, Angela; Chrétien, Michel; Figeys, Daniel; Mayne, Janice. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. The Febs Journal. 2015;282(14):2682-96. 

Rosqvist, Fredrik; Smedman, Annika; Lindmark-Månsson, Helena; Paulsson, Marie; Petrus, Paul; Straniero, Sara; Rudling, Mats; Dahlman, Ingrid; Risérus, Ulf. Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study. The American Journal Of Clinical Nutrition. 2015;102(1):20-30. 

Butkinaree, Chutikarn; Canuel, Maryssa; Essalmani, Rachid; Poirier, Steve; Benjannet, Suzanne; Asselin, Marie-Claude; Roubtsova, Anna; Hamelin, Josée; Marcinkiewicz, Jadwiga; Chamberland, Ann; Guillemot, Johann; Mayer, Gaétan; Sisodia, Sangram S; Jacob, Yves; Prat, Annik; Seidah, Nabil G. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. The Journal Of Biological Chemistry. 2015;290(30):18609-20. 

van Poelgeest, Eveline P; Hodges, Michael R; Moerland, Matthijs; Tessier, Yann; Levin, Arthur A; Persson, Robert; Lindholm, Marie W; Dumong Erichsen, Kamille; Ørum, Henrik; Cohen, Adam F; Burggraaf, Jacobus. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. British Journal Of Clinical Pharmacology. 2015;80(6):1350-61. 

Wassef, Hanny; Bissonnette, Simon; Saint-Pierre, Nathalie; Lamantia, Valérie; Cyr, Yannick; Chrétien, Michel; Faraj, May. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans. Journal Of Clinical Lipidology. 2015;9(5):664-75. 

Si-Tayeb, Karim; Idriss, Salam; Champon, Benoite; Caillaud, Amandine; Pichelin, Matthieu; Arnaud, Lucie; Lemarchand, Patricia; Le May, Cédric; Zibara, Kazem; Cariou, Bertrand. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Disease Models & Mechanisms. 2016;9(1):81-90. 

Rogacev, Kyrill S; Heine, Gunnar H; Silbernagel, Günther; Kleber, Marcus E; Seiler, Sarah; Emrich, Insa; Lennartz, Simone; Werner, Christian; Zawada, Adam M; Fliser, Danilo; Böhm, Michael; März, Winfried; Scharnagl, Hubert; Laufs, Ulrich. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. Plos One. 11(1):e0146920. 

Milasan, Andreea; Dallaire, François; Mayer, Gaétan; Martel, Catherine. Effects of LDL Receptor Modulation on Lymphatic Function. Scientific Reports. 2016;6:27862. 

Vlachopoulos, Charalambos; Terentes-Printzios, Dimitrios; Georgiopoulos, Georgios; Skoumas, Ioannis; Koutagiar, Iosif; Ioakeimidis, Nikolaos; Stefanadis, Christodoulos; Tousoulis, Dimitrios. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis. 2016;252:50-60. 

Li, Sha; Zhao, Xi; Zhang, Yan; Zhu, Cheng-Gang; Guo, Yuan-Lin; Wu, Na-Qiong; Xu, Rui-Xia; Qing, Ping; Gao, Ying; Sun, Jing; Liu, Geng; Dong, Qian; Li, Jian-Jun. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget. 2017;8(7):12333-12341. 

Navarese, Eliano P; Kolodziejczak, Michalina; Winter, Max-Paul; Alimohammadi, Arman; Lang, Irene M; Buffon, Antonino; Lip, Gregory Yh; Siller-Matula, Jolanta M. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. International Journal Of Cardiology. 2017;227:644-649. 

Suzuki, Yuta; Hyodo, Kenji; Suzuki, Takuya; Tanaka, Yohei; Kikuchi, Hiroshi; Ishihara, Hiroshi. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates. International Journal Of Pharmaceutics. 2017;519(1-2):34-43. 

Li, Sha; Guo, Yuan-Lin; Zhao, Xi; Zhang, Yan; Zhu, Cheng-Gang; Wu, Na-Qiong; Xu, Rui-Xia; Qing, Ping; Gao, Ying; Li, Xiao-Lin; Sun, Jing; Liu, Geng; Dong, Qian; Li, Jian-Jun. Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Scientific Reports. 2017;7(1):360. 

Hyrina, Anastasia; Olmstead, Andrea D; Steven, Paul; Krajden, Mel; Tam, Edward; Jean, François. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9. Ebiomedicine. 2017;23:68-78. 

Blanchard, C; Moreau, F; Ayer, A; Toque, L; Garçon, D; Arnaud, L; Borel, F; Aguesse, A; Croyal, M; Krempf, M; Prieur, X; Neunlist, M; Cariou, B; Le May, C. Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption. International Journal Of Obesity (2005). 2018;42(3):552-560. 

Iacocca, Michael A; Wang, Jian; Sarkar, Samantha; Dron, Jacqueline S; Lagace, Thomas; McIntyre, Adam D; Lau, Paulina; Robinson, John F; Yang, Ping; Knoll, Joan H; Cao, Henian; McPherson, Ruth; Hegele, Robert A. Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. The Canadian Journal Of Cardiology. 2018;34(10):1316-1324. 

Zhang, Zhong; Wei, Teng-Fei; Zhao, Bei; Yin, Zhao; Shi, Quan-Xing; Liu, Pei-Lin; Liu, Li-Feng; Liu, Li; Zhao, Jing-Tao; Mao, Shuai; Rao, Meng-Meng; Wang, Shou-Li; Chen, Yun-Dai. Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction. Scientific Reports. 2019;9(1):3113. 

Merrelaar, Anne; Buchtele, Nina; Schriefl, Christoph; Clodi, Christian; Poppe, Michael; Ettl, Florian; Herkner, Harald; Jilma, Bernd; Schwameis, Michael; Schoergenhofer, Christian. Low PCSK-9 levels Are Associated with Favorable Neurologic Function after Resuscitation from out of Hospital Cardiac Arrest. Journal Of Clinical Medicine. 2020;9(8)